Dermatology

New data from ECZTRA 1 and 2 show patients unable to achieve complete skin clearance nonetheless benefitted in at least 1 component of disease improvement.

An interview on several major highlights from Dr. Orozsco’s presentation about the greater visibility and importance of physician associates at SDPA 2022.

An interview with Dr. Orozco regarding her presentation at SDPA 2022 on the topic of physician associates and their value in the modern medical system.

An SDPA 2022 interview with Dr. Robert Kirsner regarding his presentation regarding the topic of wound healing and related changes in the field.

An interview at the SDPA 2022 Conference on major talking points from Dr. Robert Kirsner’s presentation on wound care with dermatologists and physician associates.

An interview from SDPA 2022 regarding highlights from Dr. Robert Kirsner’s presentation on dermatologists and wound healing.

Patients with psoriasis in high-impact areas may benefit from either of 2 available dosing regimens of the biologic.

Despite a Boxed Warning included in its 2017 FDA approval, the plaque psoriasis biologic was not linked to any causal cases of suicide attempts in 4-year, real-world data.

A recent research letter highlighted the importance of diversity in the field of dermatology, citing the lack of diversity among trainees in the field.

An online survey of adult patients shows a strong desire for a singular, consistent topical option.

Phase 3 trial data from the INTEGUMENT-1 study yielded positive results for roflumilast cream on atopic dermatitis patients ages 6 and up.

New registry analysis shows persistent treatment with the IL-23 improved disease in patients predominately with a history of past biologic therapies.

A discussion with Dr. Lal regarding a recent 12-week trial evaluating the use of topical berdazimer gel for molluscum contagiosum.

New research indicated that topical 5 FU for patients with vitiligo may be an option that is both a promising and cost-effective treatment for the skin condition.

A recent study highlighted some information on hidradenitis suppurativa patients and their ongoing care needs after being treated in emergency departments.

In this study, the investigators assessed risk factors in patients with DRESS syndrome receiving vancomycin to treat gram-positive infections.

An analysis of serum dupilumab treatment for atopic dermatitis patients suggests a lack of association between either response or adverse effects.

A research team described data regarding the potential of escalating adalimumab doses for certain patients with psoriasis.

A combination therapy approach may be useful for psoriasis treatment, though an 8-week regimen may not be long enough.

A discussion with Dr. Lal on the successful trials and recent approval of dupilumab as a treatment for skin inflammation.

Data indicates a greater number of physicians is a better predictor of melanoma diagnoses than UV radiation rates.

A study finds delayed puberty, a comorbidity of epidermolysis bullosa, may affect skeletal health.

The FDA recently approved a drug treatment for prurigo nodularis, studied across over 60 clinical trials.

A review examined the ways in which costs can be reduced for patients with varying types of atopic dermatitis.

The treatment resulted in significant improvements in the Eczema Area and Severity Index (EASI) scores and patient-reported outcome measure scores.